Literature DB >> 23109229

Sclerostin antibody inhibits skeletal deterioration due to reduced mechanical loading.

Jordan M Spatz1, Rachel Ellman, Alison M Cloutier, Leeann Louis, Miranda van Vliet, Larry J Suva, Denise Dwyer, Marina Stolina, Hua Zhu Ke, Mary L Bouxsein.   

Abstract

Sclerostin, a product of the SOST gene produced mainly by osteocytes, is a potent negative regulator of bone formation that appears to be responsive to mechanical loading, with SOST expression increasing following mechanical unloading. We tested the ability of a murine sclerostin antibody (SclAbII) to prevent bone loss in adult mice subjected to hindlimb unloading (HLU) via tail suspension for 21 days. Mice (n = 11-17/group) were assigned to control (CON, normal weight bearing) or HLU and injected with either SclAbII (subcutaneously, 25 mg/kg) or vehicle (VEH) twice weekly. SclAbII completely inhibited the bone deterioration due to disuse, and induced bone formation such that bone properties in HLU-SclAbII were at or above values of CON-VEH mice. For example, hindlimb bone mineral density (BMD) decreased -9.2% ± 1.0% in HLU-VEH, whereas it increased 4.2% ± 0.7%, 13.1% ± 1.0%, and 30.6% ± 3.0% in CON-VEH, HLU-SclAbII, and CON-SclAbII, respectively (p < 0.0001). Trabecular bone volume, assessed by micro-computed tomography (µCT) imaging of the distal femur, was lower in HLU-VEH versus CON-VEH (p < 0.05), and was 2- to 3-fold higher in SclAbII groups versus VEH (p < 0.001). Midshaft femoral strength, assessed by three-point bending, and distal femoral strength, assessed by micro-finite element analysis (µFEA), were significantly higher in SclAbII versus VEH-groups in both loading conditions. Serum sclerostin was higher in HLU-VEH (134 ± 5 pg/mL) compared to CON-VEH (116 ± 6 pg/mL, p < 0.05). Serum osteocalcin was decreased by hindlimb suspension and increased by SclAbII treatment. Interestingly, the anabolic effects of sclerostin inhibition on some bone outcomes appeared to be enhanced by normal mechanical loading. Altogether, these results confirm the ability of SclAbII to abrogate disuse-induced bone loss and demonstrate that sclerostin antibody treatment increases bone mass by increasing bone formation in both normally loaded and underloaded environments.
Copyright © 2013 American Society for Bone and Mineral Research.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23109229      PMCID: PMC4076162          DOI: 10.1002/jbmr.1807

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  29 in total

1.  Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling.

Authors:  Chuwen Lin; Xuan Jiang; Zhongquan Dai; Xizhi Guo; Tujun Weng; Jun Wang; Yinghui Li; Guoyin Feng; Xiang Gao; Lin He
Journal:  J Bone Miner Res       Date:  2009-10       Impact factor: 6.741

2.  Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength.

Authors:  Michael S Ominsky; Fay Vlasseros; Jacquelin Jolette; Susan Y Smith; Brian Stouch; George Doellgast; Jianhua Gong; Yongming Gao; Jin Cao; Kevin Graham; Barbara Tipton; Jill Cai; Rohini Deshpande; Lei Zhou; Michael D Hale; Daniel J Lightwood; Alistair J Henry; Andrew G Popplewell; Adrian R Moore; Martyn K Robinson; David L Lacey; W Scott Simonet; Chris Paszty
Journal:  J Bone Miner Res       Date:  2010-05       Impact factor: 6.741

3.  Bone histomorphometry: standardization of nomenclature, symbols and units (summary of proposed system).

Authors:  A M Parfitt
Journal:  Bone       Date:  1988       Impact factor: 4.398

4.  Osteocyte apoptosis is induced by weightlessness in mice and precedes osteoclast recruitment and bone loss.

Authors:  J Ignacio Aguirre; Lilian I Plotkin; Scott A Stewart; Robert S Weinstein; A Michael Parfitt; Stavros C Manolagas; Teresita Bellido
Journal:  J Bone Miner Res       Date:  2006-04-05       Impact factor: 6.741

5.  The influence of immobilization on osteocyte morphology: osteocyte differential count and electron microscopical studies.

Authors:  B Krempien; C Manegold; E Ritz; J Bommer
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1976-04-05

6.  Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis.

Authors:  Xiaodong Li; Michael S Ominsky; Kelly S Warmington; Sean Morony; Jianhua Gong; Jin Cao; Yongming Gao; Victoria Shalhoub; Barbara Tipton; Raj Haldankar; Qing Chen; Aaron Winters; Tom Boone; Zhaopo Geng; Qing-Tian Niu; Hua Zhu Ke; Paul J Kostenuik; W Scott Simonet; David L Lacey; Chris Paszty
Journal:  J Bone Miner Res       Date:  2009-04       Impact factor: 6.741

7.  Patients with high bone mass phenotype exhibit enhanced osteoblast differentiation and inhibition of adipogenesis of human mesenchymal stem cells.

Authors:  Weimin Qiu; Tom E Andersen; Jens Bollerslev; Susanne Mandrup; Basem M Abdallah; Moustapha Kassem
Journal:  J Bone Miner Res       Date:  2007-11       Impact factor: 6.741

Review 8.  Wnt and PPARgamma signaling in osteoblastogenesis and adipogenesis.

Authors:  Ichiro Takada; Alexander P Kouzmenko; Shigeaki Kato
Journal:  Nat Rev Rheumatol       Date:  2009-07-07       Impact factor: 20.543

9.  Trabecular bone tissue strains in the healthy and osteoporotic human femur.

Authors:  B Van Rietbergen; R Huiskes; F Eckstein; P Rüegsegger
Journal:  J Bone Miner Res       Date:  2003-10       Impact factor: 6.741

10.  Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin.

Authors:  Alexander G Robling; Paul J Niziolek; Lee A Baldridge; Keith W Condon; Matthew R Allen; Imranul Alam; Sara M Mantila; Jelica Gluhak-Heinrich; Teresita M Bellido; Stephen E Harris; Charles H Turner
Journal:  J Biol Chem       Date:  2007-12-17       Impact factor: 5.157

View more
  70 in total

1.  Experimental studies of bone mechanoadaptation: bridging in vitro and in vivo studies with multiscale systems.

Authors:  Genevieve N Brown; Rachel L Sattler; X Edward Guo
Journal:  Interface Focus       Date:  2016-02-06       Impact factor: 3.906

Review 2.  Osteocyte Mechanobiology.

Authors:  Yuhei Uda; Ehab Azab; Ningyuan Sun; Chao Shi; Paola Divieti Pajevic
Journal:  Curr Osteoporos Rep       Date:  2017-08       Impact factor: 5.096

3.  Predicting mouse vertebra strength with micro-computed tomography-derived finite element analysis.

Authors:  Jeffry S Nyman; Sasidhar Uppuganti; Alexander J Makowski; Barbara J Rowland; Alyssa R Merkel; Julie A Sterling; Todd L Bredbenner; Daniel S Perrien
Journal:  Bonekey Rep       Date:  2015-04-22

4.  A novel technique with reduced computed tomography exposure to predict vertebral compression fracture: a finite element study based on rat vertebrae.

Authors:  Giovanni F Solitro; Florian Mainnemare; Farid Amirouche; Ankit Mehta
Journal:  Med Biol Eng Comput       Date:  2018-11-07       Impact factor: 2.602

5.  Sclerostin is essential for alveolar bone loss in occlusal hypofunction.

Authors:  Yang Xu; Lufei Wang; Yao Sun; Xianglong Han; Tian Gao; Xin Xu; Tian Chen; Xuefeng Zhao; Huan Zeng; Yanmin Wang; Ding Bai
Journal:  Exp Ther Med       Date:  2016-03-02       Impact factor: 2.447

6.  Expression of a Degradation-Resistant β-Catenin Mutant in Osteocytes Protects the Skeleton From Mechanodeprivation-Induced Bone Wasting.

Authors:  Whitney A Bullock; April M Hoggatt; Daniel J Horan; Karl J Lewis; Hiroki Yokota; Steven Hann; Matthew L Warman; Aimy Sebastian; Gabriela G Loots; Fredrick M Pavalko; Alexander G Robling
Journal:  J Bone Miner Res       Date:  2019-08-05       Impact factor: 6.741

Review 7.  In Vivo Osteocyte Mechanotransduction: Recent Developments and Future Directions.

Authors:  Paige V Hinton; Susan M Rackard; Oran D Kennedy
Journal:  Curr Osteoporos Rep       Date:  2018-12       Impact factor: 5.096

8.  The swaying mouse as a model of osteogenesis imperfecta caused by WNT1 mutations.

Authors:  Kyu Sang Joeng; Yi-Chien Lee; Ming-Ming Jiang; Terry K Bertin; Yuqing Chen; Annie M Abraham; Hao Ding; Xiaohong Bi; Catherine G Ambrose; Brendan H Lee
Journal:  Hum Mol Genet       Date:  2014-03-14       Impact factor: 6.150

Review 9.  Inhibitors of sclerostin: emerging concepts.

Authors:  Matthew T Drake; Joshua N Farr
Journal:  Curr Opin Rheumatol       Date:  2014-07       Impact factor: 5.006

Review 10.  [Mechanobiology and bone metabolism: Clinical relevance for fracture treatment].

Authors:  M Haffner-Luntzer; A Liedert; A Ignatius
Journal:  Unfallchirurg       Date:  2015-12       Impact factor: 1.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.